Targeting Intracellular Cholesterol is a Novel Therapeutic Strategy for Cancer Treatment.
Targeting Intracellular Cholesterol is a Novel Therapeutic Strategy for Cancer Treatment.
复制标题
DOI：
10.4172/1948-5956.1000316
复制
发表时间：
2014-12-20
期刊：
影响因子：
--
通讯作者：
Rahman MM
中科院分区：
文献类型：
--
作者：
Mandal CC;Rahman MM
来自细胞培养和动物研究的大量数据证明了他汀类降胆固醇药物在调节癌细胞增殖和转移方面的预防作用。各种临床研究也支持他汀类药物的使用与降低癌症发病率之间的相关性。然而，在某些情况下，他汀类药物未能降低患癌症的风险。因为细胞内胆固醇代替血清胆固醇，可能在肿瘤发生和转移的调节中发挥至关重要的作用。癌细胞内储存胆固醇的机制可能因癌症类型和不同个体而异。本文讨论了推测他汀类药物敏感癌症的分子细节。它还强调，如果他汀类药物与特定的 microRNA (miR) 组合使用，作为抗癌疗法可能会更有效。
Substantial data from cell culture and animal studies evidence the preventive effect of statins, cholesterol lowering-drugs, in regulation of cancer cell proliferation and metastasis. Various clinical studies also support this correlation between use of statin and the reduction of cancer incidence. However, in some cases, statins have failed to decrease the risk of cancer. Since, instead of serum cholesterol, intracellular cholesterol may play a crucial role in the regulation of tumorigenesis and metastasis. The mechanism by which cholesterol is stored within cancer cells may differ among cancer types and also in different individuals. This paper discusses the molecular detail to speculate the statin-sensitive cancer. It also highlights that statins may work better as anticancer therapy if it is used with the combination of a specific microRNA (miR).